We have recently cared for an infant with neonatal hypoglycemia secondary to endogenous organic, hyperinsulinism (blood glucose 22mg/dl; insulin 92uU/ml) that was refractory to diazoxide ...

The "Congenital Hyperinsulinism Market" report has been added to ResearchAndMarkets.com's offering. The congenital hyperinsulinism market has demonstrated remarkable growth, attributed to increasing ...

Rezolute is a microcap biopharma focused on developing therapies for hypoglycemia caused by hyperinsulinism, with promising late-stage trials for RZ358 and RZ402. RZ358 targets Congenital ...

From the Peter Bent Brigham Hospital, Boston, Mass. Derick — Physician, Peter Bent Brigham Hospital. Newton — Senior Associate in Surgery, Peter Bent Brigham Hospital. Schulz — Instructor in ...

Qatar Foundation member Sidra Medicine has conducted the industry-sponsored ‘sunRIZE’ trial for paediatric congenital hyperinsulinism. The first pharmaceutical trial comes after Sidra launched ...

Ersodetug is being evaluated for the treatment of hypoglycemia due to congenital hyperinsulinism (HI). The open label arm of the study, involving infants aged 3 months to 1 year, has been ...

"FDA's granting of Orphan Drug Designation is a recognition of the serious unmet need patients with tumor hyperinsulinism face and validates the potential significant benefit that ersodetug can ...